Novartis therapy Lucentis® recommended for approval in EU to treat patients with vision loss due to Diabetic Macular Edema, a serious complication of diabetes
http://insciences.org/article.php?article_id=9605
"Lucentis was designed specifically for use in the eye, and its efficacy and safety have now been demonstrated in patients suffering loss of vision due to diabetic macular edema through a robust program of clinical trials," said David Epstein, Division Head of Novartis Pharmaceuticals.
http://insciences.org/article.php?article_id=9605
"Lucentis was designed specifically for use in the eye, and its efficacy and safety have now been demonstrated in patients suffering loss of vision due to diabetic macular edema through a robust program of clinical trials," said David Epstein, Division Head of Novartis Pharmaceuticals.
